ArticleJournal, genetic engineering & biotechnology2026
Revealing the potential of Gastrodia elata as a therapeutic candidate for degenerative diseases.
Article in Journal, genetic engineering & biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGastrodia elata is commonly used in Eastern traditional medicine, mainly for disorders and ailments related to the central nervous system. The main active phytochemical compound is gastrodin, and it has been shown to possess many neuroprotective properties. There is a lack of systematic correlation between phytochemical profiling and computational modeling. Hence, the present study was planned to investigate the phytochemical profiling of the rhizome of G. elata, evaluate its antioxidant potential, conduct molecular docking studies against biological targets related to oxidative stress and neurodegeneration, prediction of pharmacokinetic properties of gastrodin and understanding the link between phytochemical composition and pharmacological mechanisms. MATERIALS AND
methodsPowdered of dried Gastrodia elata rhizomes was extracted with ethanol using the hot percolation method. A confirmatory quantitative analysis was performed to determine the concentration of phenolic and flavonoid compounds present. Gas chromatography-mass spectrometry analysis was conducted to identify the compounds present in the extract. FTIR spectral data of the ethanolic extract of Gastrodia elata (EEGE) were obtained using a Fourier transform infrared instrument and compared with a reference standard to determine the functional groups present. The antioxidant capacity in EEGE were identified using the DPPH radical scavenging method. The main active compound of Gastrodia elata, is gastrodin. The canonical simplified molecular-input line-entry system (SMILES) format is used for biological activity prediction via online platforms. Molecular docking of gastrodin was performed using Auto Dock version 4.2. Pharmacokinetic and toxicological activities for gastrodin were conducted using the online web tools pkCSM and ProTox 3.0.
resultsThe EEGE showed the presence of alkaloids, saponins, flavonoids, glycosides, terpenoids and phenolic compounds, but the absence of steroid compounds. GC-MS analysis showed that ethane, 1,1-diethoxy- presented the highest probability and peak percentage. FTIR spectral analysis showed similarities and differences in the chemical profiles between the gastrodin standard and EEGE. Results showed both EEGE and gastrodin standard exhibited absorption peaks at 3222.33 cm
conclusionThis study confirms the presence of gastrodin as the major bioactive compound from Gastrodia elata rhizomes and attributes strong antioxidant and neuroprotective potential to it. Integrated phytochemical, in silico, and pharmacokinetic analyses support its traditional use in CNS-related disorders and highlight gastrodin as a promising and safe therapeutic candidate for oxidative stress and neurodegenerative conditions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.